Measuring the Value of Pharmacogenomics Evidence

G. P. Patrinos; C. Mitropoulou

doi:10.1002/cpt.743

Measuring the Value of Pharmacogenomics Evidence

United Arab Emirates University

University of Patras
Golden Helix Foundation

Research output: Contribution to journal › Comment/debate

22 Scopus citations

Abstract

In recent years, there is a growing need to measure the value of pharmacogenomics testing so that policymakers are well informed to decide about adopting and reimbursing pharmacogenomics testing, prioritizing pharmacogenomics research and development, and encouraging the application of companion diagnostics. Presently, there are limited economic evaluation studies of genome-guided treatment modalities that would allow decision-makers to comparatively assess the value and clinical utility of such interventions.

Original language	English
Pages (from-to)	739-741
Number of pages	3
Journal	Clinical Pharmacology and Therapeutics
Volume	102
Issue number	5
DOIs	https://doi.org/10.1002/cpt.743
State	Published - Nov 2017

Access to Document

10.1002/cpt.743

Cite this

@article{1429ab095c754ce18c8143c2c1fca89d,

title = "Measuring the Value of Pharmacogenomics Evidence",

abstract = "In recent years, there is a growing need to measure the value of pharmacogenomics testing so that policymakers are well informed to decide about adopting and reimbursing pharmacogenomics testing, prioritizing pharmacogenomics research and development, and encouraging the application of companion diagnostics. Presently, there are limited economic evaluation studies of genome-guided treatment modalities that would allow decision-makers to comparatively assess the value and clinical utility of such interventions.",

author = "Patrinos, \{G. P.\} and C. Mitropoulou",

note = "Publisher Copyright: {\textcopyright} 2017 ASCPT",

year = "2017",

month = nov,

doi = "10.1002/cpt.743",

language = "English",

volume = "102",

pages = "739--741",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Measuring the Value of Pharmacogenomics Evidence

AU - Patrinos, G. P.

AU - Mitropoulou, C.

PY - 2017/11

Y1 - 2017/11

N2 - In recent years, there is a growing need to measure the value of pharmacogenomics testing so that policymakers are well informed to decide about adopting and reimbursing pharmacogenomics testing, prioritizing pharmacogenomics research and development, and encouraging the application of companion diagnostics. Presently, there are limited economic evaluation studies of genome-guided treatment modalities that would allow decision-makers to comparatively assess the value and clinical utility of such interventions.

AB - In recent years, there is a growing need to measure the value of pharmacogenomics testing so that policymakers are well informed to decide about adopting and reimbursing pharmacogenomics testing, prioritizing pharmacogenomics research and development, and encouraging the application of companion diagnostics. Presently, there are limited economic evaluation studies of genome-guided treatment modalities that would allow decision-makers to comparatively assess the value and clinical utility of such interventions.

UR - https://www.scopus.com/pages/publications/85030867619

U2 - 10.1002/cpt.743

DO - 10.1002/cpt.743

M3 - Comment/debate

C2 - 28581028

AN - SCOPUS:85030867619

SN - 0009-9236

VL - 102

SP - 739

EP - 741

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 5

ER -

Measuring the Value of Pharmacogenomics Evidence

Abstract

Access to Document

Other files and links

Fingerprint

Cite this